{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:17:40Z","timestamp":1783469860534,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.mayocp.2019.02.029","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T07:01:06Z","timestamp":1564642866000},"page":"1467-1474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013"],"prefix":"10.1016","volume":"94","author":[{"given":"Aref","family":"Al-Kali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci","family":"Zblewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal S.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth R.","family":"Larrabee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.mayocp.2019.02.029_bib1","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2019.02.029_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2019.02.029_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.23410","article-title":"Prognostic impact of RAS mutations in patients with myelodysplastic syndrome","volume":"88","author":"Al-Kali","year":"2013","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.mayocp.2019.02.029_bib4","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2019.02.029_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mayocp.2019.02.029_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2019.02.029_bib7","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2019.02.029_bib8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.029_bib9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.029_bib10","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.029_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.mayocp.2019.02.029_bib12","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2019.02.029_bib13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.029_bib14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and prevalence of myelodysplastic syndromes: data from the D\u00fcsseldorf MDS-registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.mayocp.2019.02.029_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2019.02.029_bib16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2019.02.029_bib17","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.029_bib18","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2019.02.029_bib19","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"J\u00e4dersten","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mayocp.2019.02.029_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canep.2016.12.005","article-title":"Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012","volume":"46","author":"Bonadies","year":"2017","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.029_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.leukres.2009.03.022","article-title":"Outcome of patients with myelodysplastic syndromes in the Veterans Administration population","volume":"34","author":"Komrokji","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.mayocp.2019.02.029_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2019.02.029_bib25","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood.V124.21.3264.3264","article-title":"Clinical outcome of patients diagnosed with myelodysplastic syndrome\u2013unclassifiable (MDS-U): single center experience","volume":"124","author":"Baidoun","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2019.02.029_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.2016.68.3805","article-title":"Association between treatment facility volume and mortality of patients with multiple myeloma","volume":"35","author":"Go","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2019.02.029_bib27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2015.08.022","article-title":"Primary myelodysplastic syndromes: the Mayo Clinic experience with 1000 patients","volume":"90","author":"Gangat","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.mayocp.2019.02.029_bib28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ejca.2013.12.002","article-title":"Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010","volume":"50","author":"Dinmohamed","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619303519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T16:55:49Z","timestamp":1575478549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619303519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0025619619303519"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.02.029","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}